Brazil's Agência Nacional de Vigilância Sanitária, known as Anvisa, seized counterfeit batches of the medications Mounjaro and Ozempic on Friday [1, 2].

The seizure highlights the growing risks associated with the global demand for GLP-1 receptor agonists, which are used for diabetes and weight loss. Counterfeit pharmaceuticals pose severe health risks to patients who may receive incorrect dosages or contaminated substances instead of active medication.

Anvisa identified the fraudulent products after discovering that the batch numbers on the packaging did not match official records [1, 2]. The agency said the drugs were manufactured by companies that are not authorized to produce these medications within Brazil [1, 2].

Reports regarding the exact date of the announcement vary between sources, with some citing Friday the 10th and others citing Friday the 20th [1, 2]. However, the regulatory action confirms a targeted effort by the Brazilian government to purge the domestic market of illegal pharmaceutical replicas.

These medications have seen a surge in popularity due to their efficacy in treating obesity and type 2 diabetes. This demand has created a lucrative market for illicit producers to create convincing fakes that mimic the branding of legitimate pharmaceutical companies.

Anvisa continues to monitor the supply chain to prevent unauthorized medications from reaching consumers. The agency said that using products from non-authorized manufacturers can lead to unpredictable medical outcomes and a lack of therapeutic effect [1, 2].

“Anvisa seized counterfeit batches of the medications Mounjaro and Ozempic on Friday.”

The interception of these drugs suggests a sophisticated illicit supply chain attempting to exploit the high demand for weight-loss medications in South America. As these drugs become more central to public health strategies for obesity, regulatory bodies like Anvisa must increase surveillance to prevent the proliferation of unregulated alternatives that could cause widespread patient harm.